242 related articles for article (PubMed ID: 23167335)
1. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
2. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
[TBL] [Abstract][Full Text] [Related]
3. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
[TBL] [Abstract][Full Text] [Related]
4. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
5. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.
El-Danasouri NM; Ragab SH; Rasheed MA; Ali El Saadany Z; Abd El-Fattah SN
Ann Clin Lab Sci; 2014; 44(4):449-54. PubMed ID: 25361931
[TBL] [Abstract][Full Text] [Related]
6. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of SNP of P53 genes pathway on the adult AML patients.
Abdel Hamid TM; El Gammal MM; Eibead GT; Saber MM; Abol Elazm OM
Hematology; 2015 Jul; 20(6):328-35. PubMed ID: 25232917
[TBL] [Abstract][Full Text] [Related]
8. The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis.
Assmann G; Wieczorek S; Wibisono D; Roemer K; Arning L; Voswinkel J
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S72-5. PubMed ID: 18799058
[TBL] [Abstract][Full Text] [Related]
9. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
10. Association between single nucleotide polymorphisms in the p53 pathway and response to radiotherapy in patients with nasopharyngeal carcinoma.
Xie X; Jin H; Hu J; Zeng Y; Zhou J; Ouyang S; Yang W; Hu B; Wang H
Oncol Rep; 2014 Jan; 31(1):223-31. PubMed ID: 24173110
[TBL] [Abstract][Full Text] [Related]
11. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.
Cai X; Yang M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):555-61. PubMed ID: 22205265
[TBL] [Abstract][Full Text] [Related]
12. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
14. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.
Liu G; Cescon DW; Zhai R; Zhou W; Kulke MH; Ma C; Xu W; Su L; Asomaning K; Heist RS; Wain JC; Lynch TJ; Christiani DC
Dis Esophagus; 2010 Jan; 23(1):36-9. PubMed ID: 19302219
[TBL] [Abstract][Full Text] [Related]
15. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
16. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
[TBL] [Abstract][Full Text] [Related]
17. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
18. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome.
Assmann G; Wagner AD; Monika M; Pfoehler C; Pfreundschuh M; Tilgen W; Roemer K
Rheumatol Int; 2010 Aug; 30(10):1273-6. PubMed ID: 19779722
[TBL] [Abstract][Full Text] [Related]
19. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A
BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330
[TBL] [Abstract][Full Text] [Related]
20. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
